0001579428 2022-05-09 2022-05-09 true 0001579428 8-K/A 2022-05-09 Axsome Therapeutics, Inc. DE 001-37635 45-4241907 22 Cortlandt Street, 16th Floor New York NY 10007 (212) 332-3241 false false false false Common Stock, Par Value $0.0001 Per Share AXSM NASDAQ false As previously disclosed in the Current Report on Form 8-K filed by Axsome Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission on March 25, 2022, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Jazz Pharmaceuticals plc (Jazz Pharmaceuticals), pursuant to which the Company acquired Sunosi® (“Sunosi”) from Jazz Pharmaceuticals.On May 9, 2022, the Company filed a Current Report on Form 8-K (the “Initial Filing”) to report, among other things, that the initial closing contemplated by the Purchase Agreement occurred on May 9, 2022, following the satisfaction or waiver of the closing conditions under the Purchase Agreement.This Current Report on Form 8-K/A (this “Amendment No. 1”) amends the Initial Filing to provide the financial statements and pro forma financial information required by Items 9.01(a) and 9.01(b) of Form 8-K that were previously omitted from the Initial Filing in reliance on Items 9.01(a)(4) and 9.01(b)(2) of Form 8-K. This Amendment No. 1 does not amend any other item of the Initial Filing and all other information previously reported in or filed with the Initial Filing is hereby incorporated by reference to this Amendment No. 1.